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BACKGROUND
Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chron-
ic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also 
occurs in patients with a narrow QRS complex, which suggests the potential use-
fulness of CRT in such patients.
METHODS
We conducted a randomized trial involving 115 centers to evaluate the effect of CRT 
in patients with New York Heart Association class III or IV heart failure, a left ven-
tricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and 
echocardiographic evidence of left ventricular dyssynchrony. All patients underwent 
device implantation and were randomly assigned to have CRT capability turned on 
or off. The primary efficacy outcome was the composite of death from any cause or 
first hospitalization for worsening heart failure.
RESULTS
On March 13, 2013, the study was stopped for futility on the recommendation of 
the data and safety monitoring board. At study closure, the 809 patients who had 
undergone randomization had been followed for a mean of 19.4 months. The pri-
mary outcome occurred in 116 of 404 patients in the CRT group, as compared with 
102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confi-
dence interval [CI], 0.92 to 1.57; P = 0.15). There were 45 deaths in the CRT group 
and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 
2.93; P = 0.02).
CONCLUSIONS
In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT 
does not reduce the rate of death or hospitalization for heart failure and may increase 
mortality. (Funded by Biotronik and GE Healthcare; EchoCRT ClinicalTrials.gov 
number, NCT00683696.)
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Despite recent advances, heart fail-ure remains a common cause of death and morbidity. According to current guidelines, 
cardiac-resynchronization therapy (CRT) is indi-
cated for patients receiving stable medical thera-
py recommended by current guidelines who have 
moderate-to-severe heart failure, a left ventricu-
lar ejection fraction of 35% or less, and a QRS 
duration of 120 msec or more as assessed elec-
trocardiographically.1 However, many patients 
with heart failure have a QRS duration of less 
than 120 msec,2 and it is currently not recom-
mended that they receive CRT. Up to 50% of 
these patients show echocardiographic evidence 
of ventricular dyssynchrony3,4 and hence might 
benefit from CRT.
Single-center studies have suggested that dys-
synchrony criteria that are based on echocardio-
graphic measurements can identify patients who 
can benefit from CRT,5-7 resulting in frequent 
off-label use of CRT in patients with a narrow 
QRS complex.8 Small, randomized clinical studies 
that were not powered to assess clinically relevant 
outcomes9-14 have suggested the existence of true 
clinical equipoise, thereby setting the stage for a 
definitive outcome trial. We therefore initiated the 
Echocardiography Guided Cardiac Resynchroni-
zation Therapy (EchoCRT) study to investigate the 
effect of CRT on morbidity and mortality among 
patients with symptomatic heart failure, a narrow 
QRS complex, and echocardiographic evidence 
of left ventricular dyssynchrony.
ME THODS
STUDY DESIGN AND OVERSIGHT
The EchoCRT study was an investigator-initiated, 
international, multicenter, randomized clinical 
trial. The trial was designed by the executive com-
mittee (see the Supplementary Appendix, available 
with the full text of this article at NEJM.org) and 
sponsored by Biotronik, with support for echo-
cardiographic training and software provided by 
GE Healthcare. Biotronik was responsible for trial 
execution and monitoring. The trial protocol, avail-
able at NEJM.org, was approved by the institutional 
review board at each participating center. The study 
results were analyzed independently at the Rob-
ertson Centre for Biostatistics at the University of 
Glasgow. The first draft of the manuscript was 
written by the first author, with review by all the 
authors; there was no commercial involvement in 
the writing of the article. All the authors made 
the decision to submit the manuscript for publi-
cation. All the authors vouch for the accuracy and 
completeness of the reported findings and for 
the fidelity of this report to the trial protocol.
PATIENTS
Eligible patients were 18 years of age or older, 
with New York Heart Association (NYHA) class III 
or IV heart failure; a left ventricular ejection frac-
tion of 35% or less; a standard indication for an 
implantable cardioverter–defibrillator (ICD); sta-
ble medical therapy recommended by current 
guidelines; a QRS duration of less than 130 msec; 
a left ventricular end-diastolic diameter of 55 mm 
or more; and echocardiographic evidence of left 
ventricular dyssynchrony. Dyssynchrony was de-
fined by means of color-coded tissue Doppler 
imaging as an opposing-wall delay in the peak 
systolic velocity of 80 msec or more in apical four-
chamber or apical long-axis views or by means of 
speckle-tracking radial strain as a delay in the 
anteroseptal-to-posterior wall of 130 msec or more 
in the mid-left ventricular short-axis view.15-18 
Details of the echocardiographic evaluation of 
dyssynchrony are provided in the Supplementary 
Appendix.
Reasons for exclusion included acute decom-
pensated heart failure, intravenous inotropic ther-
apy, atrial fibrillation within the previous month, 
and bradycardia requiring pacing. Details of the 
inclusion and exclusion criteria are provided in 
the Supplementary Appendix. All the patients 
provided written informed consent.
CRT DEVICE IMPLANTATION
Patients meeting all inclusion criteria and no ex-
clusion criteria underwent implantation of a de-
vice with both CRT and ICD capability (CRT-D). 
Biotronik Lumax HF-T CRT-D systems were used 
exclusively. All the patients received atrial and 
right and left ventricular leads. Only transvenous 
lead systems legally marketed in the respective 
countries (regardless of manufacturer) were used. 
Details of device implantation are provided in the 
Supplementary Appendix. Patients who underwent 
an unsuccessful attempt at implantation received 
an ICD rather than a CRT-D and exited the study 
after enrolling in a 30-day safety registry.
RANDOMIZATION, DEVICE PROGRAMMING,  
AND FOLLOW-UP
Randomization occurred after successful implan-
tation of the CRT-D system and the adjustment of 
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821 Underwent successful CRT-D
implantation
1680 Patients were enrolled
825 Were excluded
441 Had insufficient dyssynchrony
125 Had LVEF >35%
50 Were withdrawn by investigator
45 Were excluded owing to study
closure
44 Had baseline NYHA class <III
36 Had echocardiographic
     findings incompatible with
     study participation
34 Withdrew consent
22 Had QRS duration ≥130 msec
9 Had atrial fibrillation
9 Were lost to follow-up
7 Had other reasons
3 Died
855 Had baseline assessments of:
QRS duration <130 msec
Confirmation of LVEF ≤35% by 
    echocardiographic core laboratory
LVEDD ≥55 mm
Intraventricular-dyssynchrony inclusion
criteria met
404 Were assigned to CRT group
34 Underwent unsuccessful CRT-D
implantation attempt and were included
in 30-day safety registry
405 Were assigned to control group
12 Were withdrawn before randomization
809 Underwent randomization
       93 Required medication stabilization
       and second baseline visit before
       randomization visit
46 Died
13 Were withdrawn before study closure
5 Were lost to follow-up
7 Had ventricular assist device
3 Underwent heart transplantation
7 Crossed over to control
1 Died after crossover to control
30 Died
28 Were withdrawn before study closure
6 Were lost to follow-up
10 Had ventricular assist device
5 Underwent heart transplantation
30 Crossed over to CRT
7 Died after crossover to CRT
Figure 1. Study Enrollment, Randomization, and Follow-up.
At study termination on March 13, 2013, a total of 821 patients had undergone successful implantation of a device 
for cardiac-resynchronization therapy (CRT) with a defibrillator (CRT-D). A total of 809 patients underwent random-
ization (404 patients to CRT [CRT capability turned on] and 405 to control [CRT capability turned off ]), and follow-up 
occurred at 1 month and 3 months and then every 3 months thereafter. LVEDD denotes left ventricular end-diastolic 
diameter, LVEF left ventricular ejection fraction, and NYHA New York Heart Association.
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on October 30, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;15 nejm.org october 10, 20131398
medical therapy for heart failure according to 
current guidelines. Patients were randomly as-
signed with the use of a Web-based electronic 
randomization system in a 1:1 ratio to have CRT 
capability turned on (the CRT group) or to have CRT 
capability turned off (the control group). Ran-
domization was based on permuted blocks of 
four, stratified according to country. After ran-
domization, ICD therapy was programmed on for 
all patients, and device programming was indi-
vidualized to maximize the delivery of CRT in 
the CRT group and to minimize right ventricular 
pacing in those in the control group (see the Sup-
plementary Appendix).
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Control Group
(N = 405)
CRT Group
(N = 404)
Age — yr 58.3±12.6 57.6±12.9
Male sex — no. (%) 291 (71.9) 294 (72.8)
QRS duration — msec
Reported by the study site 105.4±12.6 105.0±13.1
Reported by the core laboratory 105.5±12.1 106.1±13.1
6-Min walk distance — m 322.6±122.1 328.3±118.6
Quality-of-life score† 51.1±24.2 51.3±24.3
NYHA classification — no. (%)‡
I 3 (0.7) 2 (0.5)
II 12 (3.0) 7 (1.7)
III 374 (92.3) 385 (95.3)
IV 16 (4.0) 10 (2.5)
Biomarker for heart failure
Brain natriuretic peptide — pg/ml
Median 275 241
Interquartile range 104–600 88–516
NT-proBNP — pg/ml
Median 978 1275
Interquartile range 479–2028 488–2554
Blood pressure while sitting — mm Hg
Systolic 120.1±19.1 117.5±19.6
Diastolic 73.0±11.9 72.6±12.1
Body-mass index 31.2±12.6 30.6±11.7
Ischemic cardiomyopathy — no./total no. (%) 214/404 (53.0) 218/404 (54.0)
Myocardial infarction >3 mo previously — no. (%) 155 (38.3) 167 (41.3)
PCI >3 mo previously — no. (%) 131 (32.3) 157 (38.9)
CABG >3 mo previously — no. (%) 74 (18.3) 77 (19.1)
Hypertension — no./total no. (%) 271/402 (67.4) 262/400 (65.5)
Congenital heart disease — no./total no. (%) 10/396 (2.5) 6/399 (1.5)
Prior ischemic stroke or TIA — no./total no. (%) 47/402 (11.7) 49/401 (12.2)
Diabetes — no./total no. (%) 153/404 (37.9) 167/402 (41.5)
Chronic lung disease — no./total no. (%) 79/401 (19.7) 70/401 (17.5)
Chronic kidney disease — no./total no. (%) 42/401 (10.5) 66/402 (16.4)
Left ventricular ejection fraction — %§ 27.0±5.4 27.0±5.7
Left ventricular end-diastolic diameter — mm 66.1±7.4 66.7±7.7
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After randomization, patients underwent 
follow-up at 1 month and 3 months and then 
every 3 months thereafter until the termina-
tion of the trial, always with clinical evaluation 
and device testing and with echocardiography 
at 6 months and 12 months. Device-implanting 
physicians were aware of the study-group as-
signments, but the patients, heart-failure phy-
sicians, and study personnel completing the 
 follow-up assessments were unaware of the group 
assignments.
OUTCOME MEASURES
The primary efficacy outcome was the combina-
tion of death from any cause or first hospitaliza-
tion for worsening heart failure. The primary 
safety outcome was freedom from complications 
related to the CRT-D system at 6 months for all 
patients undergoing an attempted implantation. 
Detailed definitions of the primary outcome 
measures are provided in the Supplementary Ap-
pendix.
The prespecified secondary outcomes were as 
follows: all hospitalizations for worsening heart 
failure throughout the study; changes in NYHA 
classification after 6 months; changes in quality 
of life, as measured by the Minnesota Living with 
Heart Failure questionnaire19 (scores range from 0 
to 105, with higher scores indicating worse func-
tion, and a clinically significant difference consid-
ered to be approximately 5 points) after 6 months; 
a study-specific score20 based on the composite 
outcome of death, first hospitalization for wors-
ening heart failure (up to 24 months), and change 
in the score on the Minnesota Living with Heart 
Failure questionnaire after 6 months (see the pro-
tocol for details); and all-cause mortality.
STATISTICAL ANALYSIS
To detect a 25% reduction in the hazard of a pri-
mary outcome with 80% power, we estimated 
that 381 first primary-outcome events were re-
quired. We based our estimate of expected event 
rates on data from the Cardiac Resynchroniza-
tion–Heart Failure (CARE-HF) trial,21 with ad-
justment for the expectation of a lower event rate 
among patients with a narrow QRS complex, as 
compared with patients with a wide QRS com-
Table 1. (Continued.)
Characteristic
Control Group
(N = 405)
CRT Group
(N = 404)
Dyssynchrony qualified with the use of tissue Doppler imaging, radial 
strain, or both — no./total no. (%)
Tissue Doppler imaging 106/405 (26.2) 96/403 (23.8)
Radial strain 100/405 (24.7) 85/403 (21.1)
Tissue Doppler imaging and radial strain 199/405 (49.1) 222/403 (55.1)
Medication at randomization — no. (%)
ACE inhibitor or ARB 384 (94.8) 383 (94.8)
Aldosterone antagonist 238 (58.8) 247 (61.1)
Beta-blocker 395 (97.5) 387 (95.8)
Diuretic agent 352 (86.9) 346 (85.6)
* Plus–minus values are means ±SD. There were no significant between-group differences at baseline, except for chronic 
kidney disease (P = 0.01). Data were missing for the following characteristics: QRS width as reported by the core labora-
tory (for 6 patients in the cardiac-resynchronization–therapy [CRT] group and for 3 in the control group), distance walked 
in 6 minutes (for 7 in the CRT group and for 10 in the control group), quality-of-life score (for 1 in the CRT group and for 
2 in the control group), biomarker for heart failure (for 19 in the CRT group and for 12 in the control group), and body-
mass index (the weight in kilograms divided by the square of the height in meters; for 1 in the CRT group). Additional 
details regarding baseline characteristics are provided in Table S1 in the Supplementary Appendix. ACE denotes angio-
tensin-converting enzyme, ARB angiotensin-receptor blocker, CABG coronary-artery bypass grafting, NYHA New York 
Heart Association, PCI percutaneous coronary intervention, and TIA transient ischemic attack.
† Quality of life was assessed with the use of the Minnesota Living with Heart Failure questionnaire.19 Scores range from 
0 to 105, with higher scores indicating worse function and a clinically significant difference considered to be approxi-
mately 5 points.
‡ Patients listed here with NYHA class I or II heart failure had class III or IV heart failure when they were enrolled in the 
study. The NYHA classification changed after medical therapy was tailored according to current guidelines and before 
randomization occurred and baseline values were assessed.
§ Left ventricular ejection fraction was assessed with the use of the biplane method.
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plex. We calculated that 1132 patients would ac-
crue the required number of events over an aver-
age follow-up of 2.5 years if the final primary 
event rate in the control group was equal to 38%.
We performed all analyses according to the 
intention-to-treat principle. Baseline characteristics 
were summarized as means and standard devia-
tions for continuous variables and as counts and 
percentages for categorical variables and were 
compared with the use of two-sample t-tests and 
chi-square (or Fisher’s exact) tests, respectively. 
P values for time-to-event analyses were based 
on log-rank tests (stratified according to country 
of recruitment) with hazard ratios for treatment 
effects and 95% confidence intervals calculated 
from Cox proportional-hazards models that in-
cluded study group and country of recruitment 
as covariates. Interactions between treatment 
effects and subgroup levels were tested for in 
Cox models that included treatment and sub-
group main effects and interaction terms. Time-
to-event curves were estimated with the use of 
the Kaplan–Meier method.
Changes in NYHA class from baseline to 
6 months were analyzed as a binary outcome 
(improved condition vs. no change or deteriorat-
ed condition) with the use of a logistic-regression 
model with adjustment for country of recruit-
ment, providing odds ratios for improvement 
and corresponding 95% confidence intervals. The 
change in total score on the Minnesota Living 
with Heart Failure questionnaire (defined as the 
score at 6 months minus the score at baseline) 
was analyzed with the use of an analysis of co-
variance with adjustment for the baseline total 
score and country of recruitment, and adjusted 
mean differences between study groups and 
95% confidence intervals were calculated. All 
P values in the efficacy analysis were two-sided.
The analysis of the primary safety outcome 
aimed to exclude a complication-free rate of 70% 
or less, on the basis of an exact one-sided bino-
mial proportion test to show that the CRT-D 
system had similar complication-free rates as 
previously reported for comparable studies.22,23
R ESULT S
PATIENT ENROLLMENT AND FOLLOW-UP
Beginning in August 2008, patients were enrolled 
at 115 centers in the United States, Canada, Israel, 
Australia, and Europe. On March 13, 2013, enroll-
ment was stopped by the executive committee on 
the recommendation of the independent data and 
safety monitoring board, on the basis of futility 
with a potential for harm. No follow-up data were 
included after the study-closure date. A final 
clinical-status assessment and final device repro-
gramming to turn off CRT capability were con-
ducted, when possible, and patients were subse-
quently returned to standard care.
At study termination, 1680 patients had con-
sented to trial participation, and 809 had under-
gone randomization (404 patients to CRT and 
405 to control) (Fig. 1). A total of 825 patients 
were excluded before implantation, the majority 
of whom did not meet the echocardiographic 
inclusion criteria according to either the local 
site or the core laboratory (602 patients). The 
echocardiographic core laboratory agreed with 
the findings of the local sites regarding dyssyn-
chrony in 89.3% of the patients, excluding 10.7% 
whose degree of dyssynchrony could not be con-
fidently confirmed. An additional 34 patients 
were excluded owing to unsuccessful implanta-
tion of a CRT-D (as described in the Supplemen-
tary Appendix), and 12 withdrew from the study 
before randomization.
The mean follow-up period was 19.4 months 
for all patients and 19.8 months for surviving 
patients. The study-visit compliance rate among 
patients was 95.5%; a total of 5324 of the 5575 
required study visits were completed up to the 
date of patient withdrawal from the study. De-
tails regarding patient withdrawal, loss to fol-
low-up, and crossovers are provided in the Sup-
plementary Appendix.
CHARACTERISTICS OF THE PATIENTS AT BASELINE
The baseline characteristics of the patients who 
underwent randomization are shown in Table 1, 
and Table S1 in the Supplementary Appendix. 
These characteristics were similar in the two 
groups, although chronic kidney disease was 
more prevalent in the CRT group. The mean QRS 
duration measured by the centers was 105.0 msec 
for the CRT group and 105.4 msec for the control 
group. The QRS width at baseline was indepen-
dently measured at the electrocardiographic core 
laboratory and was repeated for crossover ap-
proval. The mean left ventricular ejection frac-
tion and variables regarding left ventricular dys-
synchrony did not differ significantly between 
the two groups.
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EFFICACY OUTCOMES
The primary outcome, death from any cause or hos-
pitalization for worsening heart failure, occurred 
in 116 of 404 patients (28.7%) in the CRT group, 
as compared with 102 of 405 (25.2%) in the con-
trol group (hazard ratio with CRT, 1.20; 95% con-
fidence interval [CI], 0.92 to 1.57; P = 0.15) (Table 2 
and Fig. 2). During the trial, 45 of 404 patients 
(11.1%) in the CRT group died, as compared with 
26 of 405 (6.4%) in the control group (hazard ra-
tio, 1.81; 95% CI, 1.11 to 2.93; P = 0.02) (Table 2). 
Table S2 in the Supplementary Appendix shows 
the causes of death, as originally adjudicated. 
There was an excess of deaths due to cardiovascu-
lar causes in patients randomly assigned to CRT 
(37 deaths, vs. 17 in the control group; P = 0.004).
Of 809 patients, 418 (51.7%) were hospitalized 
at least once during follow-up (224 patients in the 
CRT group vs. 194 in the control group). Most of 
these hospitalizations were for cardiovascular 
reasons (147 patients in the CRT group vs. 137 
in the control group; hazard ratio, 1.11; 95% CI, 
0.88 to 1.40; P = 0.36). The hospitalization rate 
for worsening heart failure did not differ signifi-
cantly between the two groups (Table 2). A total 
of 229 hospital admissions for heart failure (35.6 
admissions per 100 years of follow-up) occurred 
in the CRT group, as compared with 181 (27.6 per 
100 years of follow-up) in the control group.
Changes from baseline to 6 months with re-
spect to NYHA class and score on the Minne-
sota Living with Heart Failure questionnaire did 
not differ significantly between the study groups. 
There was also no difference between groups in 
the composite-outcome score that included death, 
first hospitalization for worsening heart failure, 
and change in score on the Minnesota Living 
with Heart Failure questionnaire. The details of 
these results are shown in Table S3 in the Sup-
plementary Appendix.
SUBGROUPS
The effects of treatment on nine prespecified 
subgroups for the primary composite outcome 
and the component outcomes are shown in Fig-
ures S1A, S1B, and S1C in the Supplementary 
Appendix. There were no significant treatment-
by-subgroup interactions for the primary out-
Table 2. Protocol-Specified Cardiovascular Outcomes.*
Outcome
Control Group  
(N = 405)
CRT Group
(N = 404)
Adjusted Hazard 
Ratio (95% CI) P Value
no. of patients with event (%)
Primary composite outcome
Death from any cause or hospitalization for  
heart failure
102 (25.2) 116 (28.7) 1.20 (0.92–1.57) 0.15
Components of primary outcome
Hospitalization for heart failure 90 (22.2) 99 (24.5) 1.16 (0.87–1.55) 0.25
Death from any cause 26 (6.4) 45 (11.1) 1.81 (1.11–2.93) 0.02
Other cardiovascular outcomes
Hospitalization for cardiovascular event 137 (33.8) 147 (36.4) 1.11 (0.88–1.40) 0.36
Death
Cardiovascular event 17 (4.2) 37 (9.2) 2.26 (1.27–4.01) 0.004
Heart failure 10 (2.5) 17 (4.2) 1.74 (0.80–3.81) 0.15
Follow-up data censored
Owing to LVAD implantation 10 (2.5) 7 (1.7) — —
Owing to heart transplantation 5 (1.2) 3 (0.7) — —
Death after data were censored owing to LVAD 
implantation or heart transplantation†
4 (1.0) 1 (0.2) — —
* Hazard ratios were calculated by means of the Cox model with adjustment for country, and P values were calculated by 
the stratified log-rank test. LVAD denotes left ventricular assist device.
† Because these deaths occurred after LVAD implantation or heart transplantation, they were not included in the analysis 
of mortality.
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come or for hospitalization for worsening heart 
failure. For all-cause mortality, there was one nom-
inally significant treatment-by-subgroup inter-
action that suggested a greater harm with CRT in 
patients less than 65 years of age (Fig. S1C in the 
Supplementary Appendix) (P = 0.02 for interaction).
SAFETY
The rate of freedom from complications related to 
the CRT-D system at 6 months was 89.6% for the 
population that included all patients who  underwent 
an attempted implantation (binomial proportion, 
0.90; 95% CI, 0.87 to 0.92; P<0.001 for excluding 
a rate ≤70%). A total of 50 patients (12.4%) in the 
CRT group had complications, as compared with 
36 (8.9%) in the control group (P = 0.11).
A total of 93 serious adverse events related to 
the device or implantation occurred in 70 of the 
404 patients in the CRT group, and 50 such events 
occurred in 45 of the 405 patients in the control 
group (P = 0.01) (Table 3). A total of 74 device-
related serious adverse events after implantation 
occurred in 55 patients (13.6%) in the CRT group, 
and 32 events in 29 patients (7.2%) in the control 
group (P = 0.003). This difference was largely driven 
by a difference of a factor of approximately three in 
the number of lead-related serious adverse events 
between the CRT and control groups (68 vs. 22). 
These events included dislodgement of the left 
ventricular lead in 14 patients (3.5%) in the CRT 
group and in 4 (1.0%) in the control group. 
Rates of implantation-related serious adverse 
events were similar between the two groups 
(19 events in 17 patients [4.2%] in the CRT 
group and 18 events in 16 patients [4.0%] in the 
control group).
The total number of patients receiving an ICD 
shock was similar between the study groups (oc-
curring in 76 [18.8%] and 63 [15.6%] patients in 
the CRT and control groups, respectively). Inap-
propriate shocks were more prevalent in patients 
in the CRT group than in those in the control 
group (20 patients [5.0%] vs. 7 [1.7%], P = 0.01).
DISCUSSION
In the EchoCRT study, the use of CRT did not reduce 
the rate of death from any cause or first hospital-
ization for heart failure among patients with symp-
tomatic heart failure, a left ventricular ejection frac-
tion of 35% or less, and a QRS duration of less than 
130 msec. The observed excess mortality with CRT 
in this trial is of clinical concern. The excess mor-
tality was due to a significant increase in the rate of 
death from cardiovascular causes among patients 
receiving CRT. There was a nonsignificant trend 
toward an increase in mortality related to heart 
failure, which was paralleled by a nonsignificant 
increase in hospitalization for heart failure. How-
ever, the interpretation of secondary outcomes in 
trials that fail to confirm the primary hypothesized 
outcome should be approached with great caution.
Mechanical dyssynchrony in our study was 
systematically assessed with the use of uniform 
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Figure 2. Kaplan–Meier Estimates for Primary-Outcome Events.
Panel A shows the Kaplan–Meier curves for the primary composite out-
come of death from any cause or hospitalization for heart failure. Panel B 
shows the Kaplan–Meier curves for death from any cause.
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equipment and a core laboratory. In addition, ad-
vanced echocardiographic techniques were used 
to assess dyssynchrony, including tissue Doppler 
imaging and speckle-tracking radial strain, which 
have been associated with outcome when the 
QRS complex is wide.16,18,24-26 Our results re-
inforce the notion that, at least until new methods 
of assessment are developed, QRS width (with 
or without mechanical dyssynchrony) remains 
the primary determinant of response to CRT.
Clinical-outcome trials may not be appropri-
ately designed to elucidate the mechanisms of 
benefit or harm associated with a therapeutic 
intervention. However, they may provide insights 
that inform future research. Since CRT-induced 
proarrhythmia in patients with a narrow QRS 
complex could account in part for the increased 
mortality among patients randomly assigned to 
active therapy in this study, the numbers of ap-
propriate and inappropriate ICD shocks were 
analyzed, both of which may contribute to an 
increase in mortality among patients who re-
ceived an ICD or CRT-D.27 Although the total 
number of patients receiving an ICD shock was 
similar between the study groups, inappropriate 
shocks were more prevalent in patients in the 
CRT group than in those in the control group.
Since unnecessary pacing may contribute to 
the development of heart failure, it is of note 
that ventricular pacing in the control group was 
negligible in this study. Patients with ischemic 
cardiomyopathy or suboptimal placement of the 
Table 3. Serious Adverse Events after Implantation, According to Study Group.*
Event
Control Group
(N = 405)
CRT Group
(N = 404)
no. of events
no. of patients 
with event (%) no. of events
no. of patients 
with event (%)
All events 732 221 (54.6) 939 259 (64.1)
Cardiovascular event 423 160 (39.5) 499 182 (45.0)
Worsening heart failure 181 93 (23.0) 213 101 (25.0)
Atrial arrhythmia 35 25 (6.2) 34 27 (6.7)
Ventricular arrhythmia 29 22 (5.4) 36 26 (6.4)
Chest pain 26 21 (5.2) 31 16 (4.0)
Other 20 17 (4.2) 21 18 (4.5)
Dyspnea 12 11 (2.7) 16 16 (4.0)
Coronary artery disease 11 10 (2.5) 13 13 (3.2)
Noncardiovascular event 259 121 (29.9) 347 155 (38.4)
Infection 54 45 (11.1) 77 58 (14.4)
Gastrointestinal disorder 41 28 (6.9) 68 43 (10.6)
Other 55 36 (8.9) 54 40 (9.9)
Respiratory disorder 38 22 (5.4) 27 14 (3.5)
Renal disorder 19 16 (4.0) 38 28 (6.9)
Musculoskeletal disorder 18 15 (3.7) 32 25 (6.2)
Nervous system disorder 5 5 (1.2) 16 13 (3.2)
CRT-D–system related 32 29 (7.2) 74 55 (13.6)
ICD lead 13 13 (3.2) 26 23 (5.7)
Lead for right atrial pacing 5 5 (1.2) 21 18 (4.5)
Lead for left ventricular pacing 4 4 (1.0) 21 18 (4.5)
Implantation related 18 16 (4.0) 19 17 (4.2)
* Data for subcategories with an incidence of less than 3.0% are not shown. Patients could have more than one event. 
CRT-D denotes cardiac-resynchronization device with defibrillator, and ICD implantable cardioverter–defibrillator.
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left ventricular lead may be at greater risk for 
arrhythmic events with CRT, but subgroup anal-
yses did not show evidence of any interactions 
between these factors and clinical outcomes. 
Although interactions of the location of the left 
ventricular lead with respect to activation or scar 
have not been examined, it is possible that this 
study did not show a benefit because the lead 
placement was not tailored to the mechanical 
abnormal substrate of patients with heart failure 
and normal or near-normal QRS duration or 
because the leads were placed in scar areas.28,29
Current guidelines do not recommend CRT 
for patients with a normal QRS duration.1 The 
mean QRS width in the CARE-HF21 trial was 
160 msec, and the majority of patients included 
in many other major trials have had a QRS du-
ration of more than 150 msec.23,30,31 A recent 
meta-analysis evaluating the effect of QRS du-
ration on the efficacy of CRT showed that CRT 
significantly reduced the rate of death from any 
cause or hospitalization among patients with a 
QRS duration of 150 msec or more, but the mag-
nitude of effect and the certainty of benefit de-
clined with shorter QRS duration.32
The excess risk of CRT among patients in-
cluded in the EchoCRT study who had heart 
failure and a narrow QRS complex is of par-
ticular concern, because it serves as a reminder 
that the implantation of left ventricular leads 
and the ongoing care of patients treated with 
CRT (which may involve subsequent manipula-
tion of the leads for improvement in pacing) are 
not without challenges. Indeed, the rate of ad-
verse events after device implantation was sig-
nificantly higher among patients in the CRT 
group than among those in the control group, 
a difference driven largely by a difference of a 
factor of three in the number of lead-related 
serious adverse events between the two groups.
In conclusion, we investigated the potential 
benefit of CRT-D in patients with systolic heart 
failure and a QRS duration of less than 130 msec. 
As compared with an ICD with inactivated CRT, 
a CRT-D did not reduce the rate of death from 
any cause or hospitalization for heart failure and 
may increase mortality among these patients.
Supported by Biotronik and GE Healthcare.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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